Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
08 1월 2024 - 10:12PM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced the selection of a development
candidate for the Company’s program targeting KAT6, an epigenetic
target that is dysregulated in breast cancer and other cancers. The
compound, named OP-3136, is an orally bioavailable, potent
KAT6A/B-selective inhibitor developed by Olema in collaboration
with Aurigene Oncology.
“We are excited to advance our KAT6 program with the nomination
of OP-3136 as a development candidate. OP-3136 has the potential to
become a new targeted therapy for breast cancer and other cancers,”
said Dr. David C. Myles, Ph.D., Chief Discovery and Non-Clinical
Development Officer of Olema Oncology. “Our KAT6 program supports
our commitment to discovering and developing new treatment options
for women living with cancer and is a natural complement to Olema’s
ongoing development of palazestrant in ER+/HER2- breast cancer. We
look forward to providing future updates on our progress with
OP-3136 development.”
Olema presented data regarding the discovery and pre-clinical
development of its KAT6 program in a poster session at the 2023
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics (ANE 2023) in Boston, Massachusetts. OP-3136 is
orally bioavailable in multiple non-clinical species with desirable
pharmacokinetics and has demonstrated highly selective and potent
activity against KAT6A and KAT6B versus other KAT family members.
In KAT6-amplified and overexpressing estrogen receptor-positive
(ER+) breast cancer cell lines, OP-3136 strongly inhibited cell
proliferation whereas KAT6-low cell lines were insensitive to the
compounds. In a non-clinical xenograft model, OP-3136 caused
dose-dependent tumor growth inhibition and tumor regression
comparable to or better than a positive-control patented KAT6
inhibitor and demonstrated synergy in combination with CDK4/6
inhibitors or palazestrant (OP-1250).
Olema is initiating non-clinical Investigational New Drug (IND)
enabling studies in order to support a potential IND submission to
the U.S. Food and Drug Administration (FDA) for OP-3136 by the end
of 2024.
About Olema OncologyOlema Oncology is a
biopharmaceutical company committed to transforming the standard of
care and improving outcomes for women living with cancer. Olema is
advancing a pipeline of novel therapies by leveraging our deep
understanding of endocrine-driven cancers, nuclear receptors, and
mechanisms of acquired resistance. In addition to our lead product
candidate, palazestrant (OP-1250), a proprietary, orally-available
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD), Olema is developing a potent KAT6 inhibitor.
Olema is headquartered in San Francisco and has operations in
Cambridge, Massachusetts. For more information, please visit us at
www.olema.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Words such as
“anticipate,” “expect,” “will,” “may,” “goal,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These statements
include those related to Olema’s preclinical program, including the
potential beneficial characteristics and potency of its KAT6
inhibitor compound and its applicability to breast and other
cancers, the potential synergistic activity of Olema’s KAT6
inhibitor compounds with CDK4/6 inhibitors or palazestrant
(OP-1250), anticipated timing of an IND submission and development
of OP-3136. Because such statements deal with future events and are
based on Olema’s current expectations, they are subject to various
risks and uncertainties, and actual results, performance or
achievements of Olema could differ materially from those described
in or implied by the statements in this press release. These
forward-looking statements are subject to risks and uncertainties,
including, without limitation, those discussed in the section
titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for
the quarter ended September 30, 2023, and future filings and
reports that Olema makes from time to time with the U.S. Securities
and Exchange Commission. Except as required by law, Olema assumes
no obligation to update these forward-looking statements, including
in the event that actual results differ materially from those
anticipated in the forward-looking statements.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024